Declining genital Warts in young women in england associated with HPV 16/18 vaccination: an ecological study

Rebecca Howell-Jones, Kate Soldan, Sally Wetten, David Mesher, Tim Williams, O Noel Gill, Gwenda Hughes, Rebecca Howell-Jones, Kate Soldan, Sally Wetten, David Mesher, Tim Williams, O Noel Gill, Gwenda Hughes

Abstract

Background: Diagnoses of genital warts (GW) in genitourinary medicine (GUM) clinics have been increasing in England for many years. In 2008, an HPV immunization program began with a bivalent vaccine (Cervarix). This was expected to markedly reduce infections and disease due to human papillomavirus (HPV) 16/18 but not HPV 6/11 infections or disease. However, from 2009 to 2011 there were decreases in reported diagnoses of GW in young females at GUM clinics.

Methods: Using data from GUM clinics and a sample of general practices (GPs) throughout England, we analyzed rates of GW diagnoses by age, year of diagnosis, and estimated immunization coverage.

Results: The overall reduction in GW diagnoses at GUM clinics between 2008 and 2011 was 13.3% among 16- to 19-year-old females, with the greatest decline of 20.8% in 17-year-olds. Declines were positively associated with estimated immunization coverage. A similar pattern was seen in GP diagnoses, but not among older women, and for other GUM consultations.

Conclusions: Several factors might contribute to declines in GW. However, the size and pattern of the declines strongly suggest that we are observing an unexpected, moderately protective effect of HPV 16/18 vaccination against GW.

Trial registration: ClinicalTrials.gov NCT00122681.

Keywords: Cervarix; HPV immunization; genital warts; surveillance.

Figures

Figure 1.
Figure 1.
Rates of genital warts diagnoses in genitourinary medicine clinics in England from 2002 to 2011 and HPV immunization coverage of females in England, by age group and year.
Figure 2.
Figure 2.
(A) Rates of first genital wart diagnosis in females (with error bars showing 95% confidence intervals) and human papillomavirus immunization coverage in England, by age and year. (B) Rates of diagnosis for human simplex virus, Neisseria gonorrhoeae, and chlamydia in genitourinary medicine clinics and HPV immunization coverage in England, by year and age. Abbreviations: CI, confidence interval; CT, Chlamydia trachomatis; GP, general practitioner; GUM, genitourinary medicine; HPV, human papillomavirus; HSV, human simplex virus.

References

    1. Health Protection Agency. Vol. 1. Health Protection Report; 2007. Trends in genital warts and genital herpes diagnoses in the United Kingdom.
    1. Health Protection Agency. Vol. 3. Health Protection Report; 2009. Trends in genital herpes and genital warts infections, United Kingdom: 1999 to 2008.
    1. Nicoll A, Hughes G, Donnelly M, et al. Assessing the impact of national anti-HIV sexual health campaigns: trends in the transmission of HIV and other sexually transmitted infections in England. Sex Transm Infect. 2001;77:242–7.
    1. Health Protection Agency. Vol. 6. Health Protection Report; 2012. Sexually transmitted infections in England, 2011.
    1. Department of Health. Annual HPV vaccine uptake in England: 2010/11. . Accessed April 2013.
    1. Lu B, Kumar A, Castellsague X, Giuliano AR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis. 2011;11
    1. Lacey CJN, Lowndes CM, Shah KV. Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006;24:35–41.
    1. Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2011;87:544–7.
    1. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ. 2008;337:a769.
    1. Lehtinen M, Palmroth J, Merikukka M, Kaasila M, Apter D, Paavonen J. Competition of vaccine and non-vaccine HPV types before and after mass-vaccination. Eurogin 2011, Lisbon [SS 2-1]
    1. Hepburn HM, Seipel M, Schwarz T, Pawlita M, Waterboer T, Kaufmann AM. Ex vivo monitoring of cellular memory responses in young women immunized with either Gardasil or Cervarix four years prior to enrollment. IPV 2009, Malmo [P-13.13]
    1. Szarewski A, Skinner SR, Garland S, et al. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low risk HPV types (PATRICIA randomised trial): an unexpected observation. 2013;208:1391–6.
    1. Department of Health. Annual HPV vaccine coverage in England in 2009/2010. . Accessed August 2011.
    1. Savage EJ, Marsh K, Duffell S, Ison CA, Zaman A, Hughes G. Rapid increase in gonorrhoea and syphilis diagnoses in England in 2011. Euro Surveill. 2012;17
    1. Health Protection Agency. Genitourinary Medicine Clinic Activity Dataset (GUMCAD) . Accessed August 2011.
    1. Annual Mid-year Population Estimates for England and Wales. Available at: . Accessed August 2013.
    1. Williams T, van Staa T, Puri S, Eaton S. Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. Ther Adv Drug Saf. 2012;3:89–99.
    1. Desai S, Wetten S, Woodhall SC, Peters L, Hughes G, Soldan K. Genital warts and cost of care in England. Sex Transm Infect. 2011;87:464–8.
    1. Yung M, Denholm R, Peake J, Hughes G. Distribution and characteristics of sexual health service provision in primary and community care in England. Int J STD AIDS. 2010;21:650–2.
    1. Hughes A, Mesher D, White J, Soldan K. Coverage of the English National HPV Immunisation Programme (2008–2011) among 12–17 year old females by area-level deprivation score. Submitted for publication 2012.
    1. Health Protection Agency. Vol. 5. Health Protection Report; 2011. Further increase in chlamydia screening coverage in 2010/11; pp. 21–3.
    1. Hughes G, Catchpole M, Rogers PA, et al. Comparison of risk factors for four sexually transmitted infections: results from a study of attenders at three genitourinary medicine clinics in England. Sex Transm Infect. 2000;76:262–7.
    1. Forster AS, Marlow LA, Stephenson J, Wardle J, Waller J. Human papillomavirus vaccination and sexual behaviour: cross-sectional and longitudinal surveys conducted in England. Vaccine. 2012;30:4939–44.
    1. Sturegard E, Johnsson A, Gustafsson E, Dillner J. Condyloma typing important for follow up of HPV vaccination. A condyloma reporting project. Lakartidningen. 2008;105:3648–50.
    1. Ball SLR, Winder DM, Vaughan K, et al. Analysis of human papillomavirus genotypes and viral loads in anogenital warts. J Med Virol. 2011;83:1345–50.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다